The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
Today, Medicare Rights Center President Fred Riccardi spoke in support of the Capping Prescription Costs Act (S. 4671/H.R. 6347), legislation to extend key Inflation Reduction Act reforms to people with group health and marketplace plans.
–Statement by Fred Riccardi, president of the Medicare Rights Center– New York, NY—As we celebrate two years since the passage
In a historic first, the Biden-Harris administration today announced the results of the initial round of drug price negotiation made
It has been two years since the passage of the Inflation Reduction Act of 2022 (IRA). The landmark legislation included
In 2023, the Centers for Medicare & Medicaid Services (CMS) opened a review to determine if Medicare should cover Preexposure
This week, the Centers for Medicare & Medicaid Services (CMS) announced a new project designed to help keep costs and
Last week, CMS released additional guidance regarding Medicare Prescription Payment Plan (MPPP) outreach and education. The MPPP, sometimes referred to
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program. Depending on the provisions targeted, this would increase beneficiary costs and increase Medicare spending.
Prior authorization is one of the processes Medicare Advantage and other private insurance companies use to manage health care utilization
Today, Medicare Rights Center President Fred Riccardi spoke in support of the Capping Prescription Costs Act (S. 4671/H.R. 6347), legislation to extend key Inflation Reduction Act reforms to people with group health and marketplace plans.
–Statement by Fred Riccardi, president of the Medicare Rights Center– New York, NY—As we celebrate two years since the passage
In a historic first, the Biden-Harris administration today announced the results of the initial round of drug price negotiation made
It has been two years since the passage of the Inflation Reduction Act of 2022 (IRA). The landmark legislation included
In 2023, the Centers for Medicare & Medicaid Services (CMS) opened a review to determine if Medicare should cover Preexposure
This week, the Centers for Medicare & Medicaid Services (CMS) announced a new project designed to help keep costs and
Last week, CMS released additional guidance regarding Medicare Prescription Payment Plan (MPPP) outreach and education. The MPPP, sometimes referred to
The Inflation Reduction Act (IRA) of 2022 made key changes in Medicare law and coverage to improve prescription drug affordability for older adults and people with disabilities. Since its passage, some stakeholders and lawmakers have targeted IRA policies for revision or repeal, especially the law’s Medicare Drug Price Negotiation Program. Depending on the provisions targeted, this would increase beneficiary costs and increase Medicare spending.
Prior authorization is one of the processes Medicare Advantage and other private insurance companies use to manage health care utilization
CELEBRATING
Help us honor 35 years of making Medicare more affordable, accessible, and equitable. Sign up to receive special alerts with ways to support our 35 years of service to older adults and people with disabilities. Learn more at www.medicarerights.org/35.
